All information is correct at time of printing and is subject to change without notice. The Devon Formulary and Referral Website is not in any way liable for the accuracy of any information printed and stored by users. For the most up-to-date information, please refer to the website.
February 2025: Fluticasone propionate and azelastine hydrochloride nasal spray commissioning policy
News
February 2025: Fluticasone propionate and azelastine hydrochloride nasal spray commissioning policy
The routine commissioning of fluticasone propionate and azelastine combination nasal spray is accepted in Devon (see Commissioning Policy for more details) and consequently, fluticasone propionate and azelastine hydrochloride nasal spray (50micrograms / 137micrograms) has been added to the formulary as an amber (specialist input) option for moderate to severe symptoms of allergic rhinitis in adults and children aged ≥12 years, following failure of combination therapy (antihistamine and nasal corticosteroid) which has been optimised by a secondary care allergy specialist (adult immunology services or specialists in paediatric allergy management).
Initiation of treatment by other specialist services is not supported.
Allergy specialists will prescribe and assess treatment response; if the product results in a sustained reduction in symptoms primary care may be asked to continue prescribing.
See here for the formulary entry.
